LABFF OTC
Laboratorios Farmaceuticos Rovi, S.A.
1W: +0.0%
1M: +0.0%
3M: -25.0%
YTD: -25.9%
1Y: -25.9%
3Y: +34.9%
5Y: +4.7%
$67.17
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$185M
+34.0% ▲
5Y CAGR: +31.6%
Capital Expenditures
$65M
-4.8% ▼
5Y CAGR: +10.4%
Free Cash Flow
$120M
+57.9% ▲
5Y CAGR: +75.6%
Dividends Paid
$48M
+15.3% ▲
Buybacks
$55M
+38.9% ▲
Net Change in Cash
$74M
+3869.2% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $183M | $258M | $220M | $178M | $140M |
| Depreciation & Amort. | $21M | $23M | $24M | $28M | $30M |
| Stock-Based Comp. | $1M | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$64M | -$57M | -$34M | $9M | -$13M |
| Other Non-Cash Items | -$6M | $14M | -$97M | -$76M | $27M |
| Operating Cash Flow | $149M | $238M | $113M | $138M | $185M |
| — Investing Activities — | |||||
| Capital Expenditures | -$41M | -$51M | -$54M | -$62M | -$68M |
| Acquisitions (Net) | $33K | $669K | $1M | -$19M | $2M |
| Investment Purchases | $0 | -$6M | $0 | $0 | -$3M |
| Investment Sales | $0 | $20K | $88K | $80K | $0 |
| Other Investing | $68K | -$585K | $478K | $171K | $2M |
| Investing Cash Flow | -$41M | -$57M | -$52M | -$81M | -$68M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$5M | -$5M | -$13M | $45M | $818K |
| Stock Repurchased | -$79M | -$177M | -$134M | -$90M | -$55M |
| Dividends Paid | -$21M | -$51M | -$69M | -$56M | -$48M |
| Other Financing | -$288K | $1M | $2M | $4M | $0 |
| Financing Cash Flow | -$63M | -$155M | -$161M | -$55M | -$47M |
| Net Change in Cash | $46M | $26M | -$100M | $2M | $74M |
| Cash End of Period | $99M | $125M | $25M | $27M | $98M |
| Free Cash Flow | $109M | $186M | $58M | $76M | $120M |